ClinicalTrials.gov
ClinicalTrials.gov Menu

Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02369848
Recruitment Status : Completed
First Posted : February 24, 2015
Results First Posted : April 18, 2018
Last Update Posted : April 18, 2018
Sponsor:
Information provided by (Responsible Party):
Shockwave Medical, Inc.

Brief Summary:
Shockwave Medical, Inc. intends to conduct a prospective, single-arm, multi-center, clinical study designed to evaluate the safety and performance of the Shockwave Lithoplasty™ System in subjects with moderate to heavily calcified peripheral arteries with 3.50mm to 7.0mm reference vessel diameter at the target site. The Shockwave Lithoplasty™ System is indicated to generate sonic shockwave energy within the target treatment site and disrupt calcium within the lesion to allow for subsequent dilation of a peripheral artery stenosis using low balloon pressure. Up to sixty (60) subjects will be enrolled and treated with Lithoplasty to yield thirty (51) evaluable subjects complete the study assuming a 15% lost to follow-up rate.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: Shockwave Lithoplasty System Not Applicable

Detailed Description:

Shockwave Medical, Inc. intends to conduct a prospective, single-arm, multi-center, clinical study designed to evaluate the safety and performance of the Shockwave Lithoplasty™ System in subjects with moderate to heavily calcified peripheral arteries with 3.50mm to 7.0mm reference vessel diameter at the target site. The Shockwave Lithoplasty™ System is indicated for lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. Up to sixty (60) subjects will be enrolled at up to 8 centers in Europe and New Zealand to yield at least 51 evaluable subjects (assuming a lost-to-follow up rate of 15%).

Subjects will be evaluated at discharge, 30 days, 6 months, and 12 months after enrollment/index procedure.

Primary endpoints include safety and efficacy. Safety is a composite of new-onset Major Adverse Events through 30 days. Efficacy is target lesion patency at 12 months by duplex ultrasound defined as freedom from ≥50% restenosis.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)
Actual Study Start Date : June 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Lithoplasty Treatment
Shockwave Lithoplasty System
Device: Shockwave Lithoplasty System



Primary Outcome Measures :
  1. Effectiveness Endpoint Defined as Number of Participants withTarget Lesion Patency by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis [ Time Frame: 12 months post-procedure ]
  2. Safety Endpoint Defined as Composite of New-onset Major Adverse Events (MAEs) [ Time Frame: Within 30 days following procedure ]

    Need for emergency surgical revascularization of target limb. Unplanned target limb amputation (above the ankle). Symptomatic thrombus or distal emboli, defined as clinical signs or symptoms of thrombus or distal emboli detected in the treated limb in the area of the treated lesion or distal to the treated lesion after the index procedure and results in extended hospitalization or noted angiographically, and requiring mechanical or pharmacologic means to improve flow and results in extended hospitalization.

    Perforations and dissections of grade D or greater that require an intervention to resolve, including bail-out stenting.



Secondary Outcome Measures :
  1. Safety Measured by Number of Participants With Freedom From Major Adverse Events (MAEs) [ Time Frame: 12 months ]
  2. Secondary Endpoint of Acute Procedural Success Achieved in Number of Participants [ Time Frame: Day of Procedure ]
    1. The ability of the Shockwave Lithoplasty System to achieve a post-Shockwave residual diameter stenosis of <50% (with or without adjunctive Percutaneous Transluminal Angioplasty (PTA) therapy) as assessed by quantitative angiography via core lab evaluation.
    2. The ability of the Shockwave Lithoplasty System to achieve a post-Shockwave residual diameter stenosis of <50% (without adjunctive PTA therapy) as assessed by quantitative angiography via core lab evaluation.

  3. Secondary Patency Measured by Number of Participants With Target Lesion Patency by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis. [ Time Frame: 6 months ]
  4. Secondary Patency Measured by Number of Participants With Target Lesion Patency (Without Adjunctive PTA) by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis. [ Time Frame: 12 months ]
  5. Clinical Success - Improvement of Ankle-Brachial Index (ABI) of the Target Limb. [ Time Frame: 6 months ]
    The ankle-brachial pressure index or ankle-brachial index is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD).

  6. Clinical Success - Improvement of Ankle-Brachial (ABI) of the Target Limb. [ Time Frame: 12 months ]
    The ankle-brachial pressure index or ankle-brachial index is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. It has been shown to be a specific and sensitive metric for the diagnosis of Peripheral Arterial Disease (PAD).

  7. Clinical Success [ Time Frame: 6 months ]

    Change in Rutherford Clinical Category at from Baseline to 6 months.

    There are seven stages to consider:

    Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.

    Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene


  8. Clinical Success [ Time Frame: 12 months ]

    Change in Rutherford Clinical Category from Baseline to12 months.

    There are seven stages to condsider:

    Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.

    Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene


  9. Clinical Success [ Time Frame: 30 days ]

    Change in Rutherford Clinical Category from Baseline to 30 days

    There are seven stages to condsider:

    Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.

    Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is able and willing to comply with all assessments in the study.
  2. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.
  3. Age of subject is >18.
  4. Rutherford Clinical Category 2, 3, or 4.
  5. Resting ankle-brachial index (ABI) of ≤0.90, or ≤0.75 after exercise, of the target leg.
  6. Estimated life expectancy >1 year.

Angiographic Inclusion Criteria:

  1. Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guideline.
  2. Target lesion that is located in a native de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery).
  3. Target lesion reference vessel diameter is between 3.50mm and 7.0mm by visual estimate.
  4. Target zone is ≤150mm in length. Target lesion can be all or part of the 150mm zone.
  5. Target lesion is ≥70% stenosis by investigator via visual estimate.
  6. Subject has at least one patent tibial vessel on the target leg with runoff to the ankle (not supported by collateral circulation.) Tibial vessel patency is defined as no stenosis >50%.
  7. Ability to pass the guidewire across the atherosclerotic lesion.
  8. No evidence of aneurysm or acute or chronic thrombus in target vessel.
  9. Calcification is at least moderate. (Presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending ≥ 50% the length of the lesion.)

Exclusion Criteria:

  1. Rutherford Clinical Category 5 and 6.
  2. Subject has active infection in the target leg.
  3. Planned major amputation of the target leg (transmetatarsal or higher).
  4. The use of chronic total occlusion (CTO) re-entry devices.
  5. CTOs greater than 80 mm in length.
  6. Any in-stent restenosis within the target zone.
  7. Lesions within 10 mm of ostium of the SFA.
  8. Highly tortuous arteries (bends greater than 30 degrees over the arc length of the balloon).
  9. Target lesion within native or synthetic vessel grafts.
  10. History of prior endovascular or surgical procedure on the index limb within the past 30 days.
  11. Subject has significant stenosis (>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g. iliac or common femoral) not successfully treated with Plain old Balloon Angioplasty (POBA) or stent and without complications.
  12. Subject requires treatment of a peripheral lesion on the ipsilateral limb distal and beyond the 150mm target zone at the time of the enrollment/index procedure.
  13. Subject has a known coagulopathy or has a bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter, or International Normalized Ratio (INR) >1.5.
  14. Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated.
  15. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
  16. Subject has known allergy to urethane, nylon, or silicone.
  17. Myocardial infarction within 60 days prior to enrollment.
  18. History of stroke within 60 days prior to enrollment.
  19. History of unstable coronary artery disease or other uncontrollable comorbidity resulting in hospitalization within the last 60 days prior to enrollment.
  20. History of thrombolytic therapy within two weeks of enrollment.
  21. Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L), or on dialysis.
  22. Subject is pregnant or nursing.
  23. Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
  24. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02369848


Locations
Austria
Universitätsklinikum LKH Graz
Graz, Austria
Hanusch Krankenhaus
Vienna, Austria
Medizinische Universitat Wien
Vienna, Austria
Germany
Universitäts-Herzzentrum Freiburg & Bad Krozingen
Bad Krozingen, Germany
University Leipzig Medical Centre
Leipzig, Germany
St. Franziskus Hospital
Munster, Germany
RoMed Klinikum Rosenheim
Rosenheim, Germany
New Zealand
Auckland City Hospital
Auckland, New Zealand
Sponsors and Collaborators
Shockwave Medical, Inc.
Investigators
Principal Investigator: Thomas Zeller, MD Universitäts-Herzzentrum Freiburg & Bad Krozingen

Responsible Party: Shockwave Medical, Inc.
ClinicalTrials.gov Identifier: NCT02369848     History of Changes
Other Study ID Numbers: TD 0232
First Posted: February 24, 2015    Key Record Dates
Results First Posted: April 18, 2018
Last Update Posted: April 18, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases